## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($244.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: Finviz | 20251230T220830 | Neutral | Relevance: 100%
- Labcorp announced its participation in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, at 4:30 p.m. PT. A live audio webcast will be available on the company's investor relations website. Labcorp, a global leader in laboratory services, provides diagnostics and drug development capabilities, serving clients in approximately 100 countries.

**2. Labcorp Holdings Inc to Participate in J.P. Morgan Healthcare Conference**
- Source: TradingView — Track All Markets | 20251230T212517 | Neutral | Relevance: 100%
- Labcorp Holdings Inc (LH) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The company will join a fireside chat on January 13, 2025, which will be webcast live on Labcorp's Investor Relations site and subsequently archived for replay. This announcement was made via an SEC filing on December 30, 2025.

**3. Labcorp to Present at J.P. Morgan Healthcare Conference**
- Source: TipRanks | 20251230T215317 | Somewhat-Bullish | Relevance: 100%
- Labcorp Holdings will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. This presentation aims to engage with the investment community regarding Labcorp's diagnostics and drug development contributions. Analysts currently rate LH stock as a Buy with a $308.00 price target, and TipRanks’ AI Analyst, Spark, also provides an "Outperform" rating, indicating a positive outlook despite some bearish technical indicators.

**4. Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: WV News | 20251230T211717 | Neutral | Relevance: 100%
- Labcorp (NYSE: LH) announced its participation in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference. The event is scheduled for Tuesday, January 13, at 4:30 p.m. PT, and a live audio webcast will be available on Labcorp's Investor Relations website. The company is a global leader in laboratory services, supporting healthcare decisions and drug development.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.0B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 14.4 |
| Current P/E | 15.5 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.2% to -0.8% (+2.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Below SMA200 (0.98x), long-term trend not supportive. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.80% (CS: 36) | Neutral |
| RSI_14 | 39.4 | Neutral |
| MACD Histogram | -0.39 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.981x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $253.12
- **Stop Loss:** $244.42 (3.4% risk)
- **Target:** $261.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 151
- **Position Value:** $38,221.12
- **Portfolio %:** 38.22%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*